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Diarrhea, in the context of human immunodeficiency virus (HIV) infection, is an enormously
important clinical issue (Smith et al., 1988). Diarrhea in patients with AIDS is extremely
problematic for both patient and clinician. More than 50% of AIDS patients suffer from diarrhea,
the cause of which is unexplained in most of the cases. The causes of diarrhea in HIV infection
are multifactorial. Chiefly, these may be caused by the primary retroviral infection per se, several
opportunistic infections, alteration of gut microbiome, immune reconstitution, water sanitation or
as a complication of highly active anti-retroviral therapy (HAART) like didanosine or ritonavir, and
may also result from induced pancreatic insufficiency (Haas et al., 2011; Saha et al., 2011; Murray
and Rubio-Tapia, 2012; Vyas et al., 2012; Agholi et al., 2013; Martin et al., 2013; Clay and Crutchley,
2014; Dye, 2014; Dikman et al., 2015; Green et al., 2015; Rubaihayo et al., 2015; Yates et al., 2015).
The diarrhea in primary HIV infection is primarily secretory in nature (Juckett and Trivedi, 2011;
MacArthur and DuPont, 2012). Some preliminary studies have suggested the role of viral proteins
in causation and aggravation of diarrhea in HIV infected patients. For example, retroviral tat
proteins have been demonstrated to enhance myenteric neuronal excitability by altering different
sodium channels (Ngwainmbi et al., 2014). It is obvious that inHIV infection, a viral specific protein
that affects genomic transcription would affect diverse cellular mechanism (s). This opinion piece
advances a concept of how HIVmay gain entry into the gastrointestinal mucosa using an upstream
neuropeptide mechanism, providing a perspective of an incipient mechanism involved in mucosal
disease caused by HIV and potential druggable targets for HIV induced diarrhea.
Namely, the hypothesis is based on two key reported observations: (i) the molecular overlap of
a pentapeptide belonging to gp120, the key viral envelope protein that helps in cellular docking
and a segment of vasoactive intestinal polypeptide (VIP) (Pert et al., 1988). HIV have been
variously reported to bind to the VIP receptors, VPAC1 and VPAC2, and produce differential
effects (see below). (ii) The earliest observations from HIV infected patients of the elevation of
serum VIP during primary HIV illness and diarrhea (Manfredi et al., 1993, 1994). Potentially, how
primary mucosal HIV infection causes elevation of serum VIP in not known. Here a rationale is
presented that has striking similarity to a mechanism similar to Clostridium difficile diarrhea, one
which involves disruption of cytoskeletome of mucosal epitheliocyte (Farrell and LaMont, 2000;
Kumar et al., 2014). The tat proteins, through transcriptional activation, may hijack and alter the
cytoskeletal machinery, thus resulting in leakage of cellular peptides like VIP (Vitale et al., 2013).
This may also occur from submucosal neurons which are rich in VIP (Vitale et al., 2013). It is well
known that excessive VIP in the mucosal extracellular space may cause secretory diarrhea (Krejs
et al., 1980; Chambers et al., 2005), much like that seen in VIPoma (Krejs et al., 1977). There are only
scant reports which have examined the electrolyte composition of diarrheal stool in HIV diarrhea
or examined mucosal flux of electrolytes by Ussing’s chamber after retroviral mucosal loading, but
is generally agreed that it is of the secretory type (Schiller et al., 1994; Stockmann et al., 2000;
Nwachukwu and Okebe, 2008).
The initial rise in VIP secretion may be related to a beneficial microenvironment of immune
resistance. VIP have been reported to reduce viral production in HIV-1-infected human primary
macrophages (Souza et al., 2014). The exact mechanisms of transfer of HIV-1 into gut mucosal
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and nerve terminals is not precisely known. Importantly, HIV-1
does not replicate in neurons and its productive infection in other
cell types leads to the release of neurotoxic viral proteins, such as
Tat, Nef, Vpr, and gp120 (Souza et al., 2014). These peptides may
cause neuronal apoptosis. These neuroplastic aspects affecting
the enteric nervous system (ENS) merits further studies. VIP
exerts anti-inflammatory activity by inhibiting the activity or
production of the interleukins IL-12, IL-6, IL-1β, tumor necrosis
factor (TNF-α) and macrophage migration inhibitory factor,
and stimulate the production of anti-inflammatory factors like
IL-4 and IL-10. VIP and PACAP also participate in Th2 cell
differentiation and inhibit synthesis of the Th1 cytokines IFN-γ
and IL-2 (Souza et al., 2014). Additionally, VIP induces tolerance
development in dendritic cells, induces the differentiation of T
regulatory cells (Tregs) and reduces TLR2 and TLR4 expression
on CD4+T cells (Chorny et al., 2006; Delgado and Ganea, 2013).
It is known that viral antigen-induced cell death (AICD) is
mediated by the T cell receptor (TCR) and involves Fas/Fas ligand
(FasL) interactions. By affecting the expression of FasL. VIP may
play significant role in the inhibition of FasL-mediated T cell
cytotoxicity (Delgado and Ganea, 2000) and potentially alter the
course of primary mucosal HIV infection. An important area of
investigations would be how the intraepithelial lymphocytes and
dendritic cells fail to mount adequate antiviral response after the
initial infections and the role of CD25-FoxP+ve Treg cells (Wang
et al., 2015).
The small homology (five amino acids) between VIP peptide
sequences and the variable region V2 of HIV-1 gp120 (Sacerdote
et al., 1987) suggest that VIP and their receptors might potentially
participate in the pathogenesis of AIDS. These initial suggestive
hypothesis came during exploration of possible mechanisms of
neurocognitive complications that arose in the HIV infected
populations (before the era of HAART) (Ngwainmbi et al., 2014).
It has been proposed that VIP could block HIV-1 entry into
target cells through direct interaction with the CD4 molecule
(Souza et al., 2014). VIP also could act as a blocking peptide
by binding to gp120, and prevent HIV binding to target cells.
Additionally, these peptides may modulate transfer of HIV
from macrophages/dendritic cells to mucosal epitheliocyte and
submucosal neurons. These aspects merits systematic testing.
VIP receptor activation by HIV-1 produces opposing effects.
It has been reported that productive HIV-1 infection can be
facilitated by the sole activation of VPAC1, one of the major
receptor classes for VIP (Bokaei et al., 2007). On the other
hand, viral production is reduced in HIV-1-infected cells either
following the engagement of VPAC2, the other major receptor
for VIP (Branch et al., 2002). However, when cells are treated
with VIP, with resultant engagement of both VPAC1 and VPAC2,
HIV-1 production is reduced in the target cells (Temerozo
et al., 2013). An initial pilot study could not detect the effect of
VIP receptors (Nguyen, 1988). The precise mechanism for this
disconcordant observation is not known but may have resulted
from lack of examination of the multitude of splice variants of
VIP receptors (Bokaei et al., 2006) and differential selectivity
of peptide fragments and full-length VIP sequence on binding
affinity to its receptors (Rorstad et al., 1990).
If mucosal ulcer occurs with HIV infections and viral entry
is not well known. In other organs, HIV is known to cause
epitheliocyte damage. For example, HIV associated nephropathy
(HIVAN) is associated with collapsing glomerulitis (Rosenberg
et al., 2015). This epithelial damage is known to be associated
with alteration of transcription factors like snail (Kumar et al.,
2011). Snail regulates the genomic expression of different kinds
of myosin by acting on its promoter (Chaudhury et al., 2014).
Whether HIV alters myosin promoter expression and functions
after retroviral genome integration merits further investigation.
Additional hypotheses have been posited about HIV mucosal
disease. Preliminary suggestions have beenmade aboutmorphine
based mechanisms of HIV mucosal illness, based on empiric
observations of worsening HIV primary disease in opioid abusers
(Samikkannu et al., 2015; Sindberg et al., 2015; Weisberg
et al., 2015). This correlation may not be necessarily be
mechanistic, as morphine based mechanism in general inhibit
oro-aboral transit of luminal contents and anti-diarrheal in its
summative pharmacologic manifestations. Furthermore, apart
from opioid abuse, injection drug use may produce a number
of confounding situations in HIV infected people including
hepatitis C virus (HCV) coinfections. A common route of HIV
entry, apart from being in circulation, are sexual practices like
anal penetration exercised by preferences like men having sex
with men (MSM) (Wahome et al., 2013). Whether such acts
cause mucosal entry and acts as a nidus for HIV entry and
how VIP contributes to these process merits further exploration.
HIV infected populations are exposed to the risk of multiple
sexually-transmitted infections (STI), including syphilis (Jia et al.,
2015; Taylor et al., 2015), and which is prevalent in epidemic
proportions across the globe. Syphilis may cause Crohn’s like
colitis-type proctitis (Davis and Goldstone, 2009; Lamb et al.,
2013), especially with prevalent sexual practices, and these
mucosal lesions may also favor HIV dissemination through the
inflamed mucosa.
The first-in-class agent crofelemer has been recently FDA
(US Food and Drug Administration) approved to manage
HIV and HAART- induced non-infectious diarrhea (Crutchley
et al., 2010). Crofelemer derived from extract of Croton lechleri
(dragon’s blood, Sangre de Drago/Sangre de Grado) blocks the
chloride channels CFTR and TMEM16A. This is an end point
mechanism for inhibiting chloride secretion-induced water drag
and resulting secretory diarrhea. VIP in the extracellular space
may be related to creating an antiviral environment, but at
the cost of inducing secretory diarrhea, which upon chronic
persistence may often be fatal and contribute to marked cachexia.
Some recent hypotheses have suggested the plausible role of ENS-
stimulated VIP release and its protective effects on intestinal
epithelial barrier (Ben-Horin and Chowers, 2008). HIV has also
been proposed to cause non-malabsorptive diarrhea by affecting
leak flux mechanism in a small series of duodenal biopsies
(Stockmann et al., 1998). The effect of HIV infection on barrier
function is an important area of future investigation. If the VIP
receptor mechanisms for HIV viral entry into the gastrointestinal
mucosa are further validated, blocking the pentapeptide by
heteroclitic peptide or a blocking antibody could become a simple
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but potent vaccine strategy to prevent HIV diarrhea and control
persistence and spread of the retrovirus.
In summary, HIV associated diarrhea remains a major
cause of morbidity and mortality even now, with presentations
comparable to the earliest report of “slim disease”, the cachectic
manifestation, from rural Uganda (Serwadda et al., 1985). Public
health measures and reductionistic bench side approaches are
needed for appropriate rationale management of this global
pandemic of HIV- associated diarrhea.
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